Want to see LFWD full AI Analyst Report?
Top Page
Lifeward
(NASDAQ:LFWD)
Select Model
Select Model
Rating:51Neutral
Price Target:
$9.00
▲(32.55% Upside)
Action:Reiterated
Date:07/08/26
LFWD scores modestly below-average primarily due to weak financial performance: persistent losses, sustained cash burn, and a reported zero equity position outweigh the benefit of low leverage. Technicals are supportive with strong momentum versus key moving averages, but overbought indicators increase near-term risk. Earnings commentary and recent financing improve liquidity and show cost/burn progress, yet the revenue decline, margin pressure, and execution risk (AlterG shipment catch-up) keep the overall profile cautious.
Positive Factors
ReWalk sales & reimbursement expansion
Sustained ReWalk unit growth combined with expanding payer coverage and broader distribution creates structurally higher addressable demand. Durable reimbursement relationships and international distribution reduce single-market reliance and improve long-term adoption and replacement cycles for device sales and recurring service revenue.
Negative Factors
Sustained cash burn
Persistent negative operating and free cash flow forces ongoing external financing, raising dilution and creditor risk. Without a consistent path to positive cash generation, operational plans and product investments are constrained and the company remains vulnerable to funding cycles and cost-of-capital shifts.
Read all positive and negative factors
Positive Factors
Negative Factors
ReWalk sales & reimbursement expansion
Sustained ReWalk unit growth combined with expanding payer coverage and broader distribution creates structurally higher addressable demand. Durable reimbursement relationships and international distribution reduce single-market reliance and improve long-term adoption and replacement cycles for device sales and recurring service revenue.
Read all positive factors
Lifeward (LFWD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$22.86M
Dividend YieldN/A
Average Volume (3M)316.99K
Price to Earnings (P/E)―
Beta (1Y)1.18
Revenue Growth-17.67%
EPS Growth46.19%
CountryUS
Employees80
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-19.66
Shares Outstanding2,814,409
10 Day Avg. Volume318,606
30 Day Avg. Volume316,993
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)9.55
Price to Sales (P/S)3.64
P/FCF Ratio-4.77
Enterprise Value/Market Cap0.38
Enterprise Value/Revenue0.41
Enterprise Value/Gross Profit1.13
Enterprise Value/Ebitda-0.51
Forecast
1Y Price Target
$10.00Price Target Upside47.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.43
Revenue Forecast (FY)$28.29M
Lifeward Business Overview & Revenue Model
Company Description
Lifeward Ltd. is a healthcare technology company specializing in the creation, development, and commercialization of wearable robotic exoskeletons. These sophisticated devices are engineered to restore lower limb mobility for individuals living wi...
How the Company Makes Money
Lifeward makes money primarily by selling its robotic-assisted mobility products and associated support offerings. Key revenue streams include: (1) Product sales of exoskeleton systems (notably the ReWalk platform) to rehabilitation hospitals/clin...
Lifeward Earnings Call Summary
Earnings Call Date:May 15, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Neutral
Balanced mix of strategic, financial and operational positives (acquisitions, stronger cash position, ReWalk growth, cost reductions and reduced cash burn) offset by meaningful near-term operational headwinds (22% revenue decline, 800 bps gross margin compression, increased GAAP loss and manufacturing/supply chain disruptions). Management expects to resolve AlterG timing issues across Q2–Q3, sees a path to profitability and holds revenue expectation similar to prior year but retains execution risk during the transition.Positive Updates
Strategic Acquisition of Oratech
Completed equity-based acquisition of Oratech, gaining a protein oral delivery platform (including ORMD-0801 oral insulin expected to start Phase II). Transaction described as capital-efficient with minimal near-term operational burden and no material increase in operating expenses.
Negative Updates
Quarterly Revenue Decline
Total revenue for Q1 2026 was $3.9 million vs. $5.0 million in Q1 2025, a decline of approximately 22%, primarily due to reduced AlterG shipments from temporary supply chain and working capital constraints.
Read all updates
Q1-2026 Updates
Positive
Negative
Strategic Acquisition of Oratech
Completed equity-based acquisition of Oratech, gaining a protein oral delivery platform (including ORMD-0801 oral insulin expected to start Phase II). Transaction described as capital-efficient with minimal near-term operational burden and no material increase in operating expenses.
Read all positive updates
Company Guidance
Management did not raise formal 2026 guidance but reiterated they expect full‑year revenue to be similar to 2025, with the Q1 shortfall ($3.9M vs. $5.0M in Q1‑2025) to be largely made up across Q2–Q3 as AlterG backlog ships (potentially resolved by Q3); they highlighted ReWalk revenue up 11% YoY to $1.6M, gross margin down to 34.2% from 42.2% (~800 bps, 75–85% due to FX and tariffs and the rest from lower absorption), total operating expenses of $11.7M (including a ~$4.9M one‑time noncash R&D charge), adjusted Opex down 12% to $5.9M (from $6.8M), GAAP operating loss of $10.3M and unchanged adjusted operating loss of $4.6M, cash used in operations down 33% to $3.7M, and liquidity improved to $11.4M unrestricted cash (vs. $2.2M at YE‑2025) after a $10M convertible financing and ~ $6.5M cash from the Oratech acquisition, positioning the company for operational stabilization and a clearer path to profitability into late 2026/2027.Lifeward Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.92M | 22.03M | 25.66M | 13.85M | 5.51M | 5.97M |
| Gross Profit | 7.65M | 8.43M | 8.22M | 4.45M | 1.91M | 2.90M |
| EBITDA | -16.94M | -19.34M | -24.93M | -20.28M | -18.90M | -12.39M |
| Net Income | -25.87M | -19.91M | -28.94M | -22.13M | -19.57M | -12.74M |
Balance Sheet | ||||||
| Total Assets | 33.42M | 22.90M | 30.49M | 63.19M | 74.24M | 94.75M |
| Cash, Cash Equivalents and Short-Term Investments | 11.42M | 2.17M | 6.94M | 28.08M | 67.90M | 88.34M |
| Total Debt | 8.81M | 4.39M | 880.00K | 1.90M | 897.00K | 1.06M |
| Total Liabilities | 27.13M | 14.49M | 11.64M | 16.68M | 6.07M | 5.37M |
| Stockholders Equity | 6.29M | 8.41M | 18.85M | 46.51M | 68.17M | 89.38M |
Cash Flow | ||||||
| Free Cash Flow | -15.02M | -16.83M | -21.72M | -20.75M | -17.92M | -11.52M |
| Operating Cash Flow | -15.01M | -16.83M | -21.72M | -20.67M | -17.89M | -11.47M |
| Investing Cash Flow | 6.49M | -16.00K | 0.00 | -18.15M | -25.00K | -47.00K |
| Financing Cash Flow | 14.15M | 12.20M | 0.00 | -992.00K | -2.50M | 79.51M |
Lifeward Technical Analysis
Positive
6.79
Price Trends
7.14
Positive
6.84
Positive
7.31
Positive
Market Momentum
0.32
Negative
61.84
Neutral
58.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFWD, the sentiment is Positive. The current price of 6.79 is below the 20-day moving average (MA) of 7.32, below the 50-day MA of 7.14, and below the 200-day MA of 7.31, indicating a bullish trend. The MACD of 0.32 indicates Negative momentum. The RSI at 61.84 is Neutral, neither overbought nor oversold. The STOCH value of 58.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LFWD.
Lifeward Risk Analysis
Lifeward disclosed 43 risk factors in its most recent earnings report. Lifeward reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lifeward Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $22.86M | -0.41 | -127.95% | ― | -17.67% | 46.19% | |
49 Neutral | $6.36M | ― | -279.58% | ― | 107.26% | 71.98% | |
46 Neutral | $9.73M | -0.08 | -164.92% | ― | -9.46% | 18.03% | |
46 Neutral | $38.48M | -0.14 | -49.65% | ― | -95.74% | -118.94% | |
42 Neutral | $5.13M | -1.59 | -84.30% | ― | -23.81% | 32.96% | |
42 Neutral | $41.85K | >-0.01 | ― | ― | ― | ― |
* Healthcare Sector Average
LFWD
Lifeward
8.12
-0.88
-9.82%
BMRA
Biomerica
1.66
-1.68
-50.30%
CODX
Co-Diagnostics
2.64
-4.92
-65.06%
XAIR
Beyond Air
0.44
-3.46
-88.69%
PAVM
PAVmed
5.38
-12.63
-70.14%
DHAI
DIH Holdings US, Inc Class A
0.02
-6.70
-99.70%
Lifeward Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Lifeward Announces New Convertible Notes and Warrants Financing
Positive
Jul 7, 2026
On June 30, 2026, Lifeward entered into amended and restated senior secured convertible notes, common warrants, and pre-funded warrants with Oramed Pharmaceuticals Inc. and certain investors, revising pari passu treatment, mandatory redemption, an...
Business Operations and StrategyExecutive/Board Changes
Lifeward Names Keith D. Rose as Chief Medical Officer
Positive
May 19, 2026
On May 18, 2026, Lifeward Ltd. announced that it had appointed Keith D. Rose, M.D. as Chief Medical Officer, effective May 1, 2026, reinforcing its leadership bench in neurosciences-focused medical affairs. Dr. Rose brings extensive experience fro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.